-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Objective: To evaluate the effects of rheumatoid arthritis (RA) and disease-modifying antirheumatic drugs (DMARDs) on intestinal permeabilit.
Methods: To investigate the integrity of the colonic mucosa, the claudin proteins ZO-1, occludin and claudin-2 were quantified by immunohistochemical staining in colon biopsies from 20 RA patients and 20 age- and sex-matched control.
To explore intestinal permeability, in another cohort of 59 RA patients—21 DMARDs-naïve patients (17 before and after introduction of conventional synthetic (cs) DMARDs), 38 severe RA patients (before and after introduction of biologics) (b) before and after DMARD), and 33 healthy controls, serum concentrations of LPS-binding protein (LBP), sCD14, and zonulin-related protein (ZRP) were assessed by ELIS.
Results: The expression of ZO-1 protein in colon of RA patients was lower than that of controls (mean score ± SE: 6 ± 56 vs 0 ± 43, p=01), while no significant difference was detected in occludin and claudin-2.
Serum LBP and sCD14 concentrations were higher in RA patients than in control.
Unlike bDMARD non-responders and patients treated with csDMARDs, bDMARD responders had significantly lower LBP and sCD14 concentration.
Conclusions: Colonic tight junction proteins are altered in RA patients and serum biomarkers of intestinal permeability are increase.
Source:
Audo R, Sanchez P, Rivière B, et a.